Abstract-The expression of apolipoprotein (apo) B can be modulated by mRNA editing, a unique posttranscriptional base change in the apo B mRNA. Apo B-48, the translation product of edited apo B mRNA, is not a precursor of the atherogenic low density lipoproteins and lipoprotein(a). In humans and various other mammals, the apo B mRNA is edited in the intestine but not in the liver, which exclusively secretes apo B-100 -containing lipoproteins as precursors for low density lipoprotein formation. In species such as the rat, mouse, dog, and horse, apo B mRNA is also edited in the liver, resulting in low plasma levels of low density lipoprotein. Editing of the apo B mRNA is mediated by the apo B mRNA-editing enzyme complex, of which the catalytic subunit APOBEC-1 is not expressed in the liver of species without hepatic editing. To understand the molecular basis for liver-specific expression of APOBEC-1 and the editing of hepatic apo B mRNA, the expression pattern and genomic organization of the rat APOBEC-1 gene have been characterized. The rat APOBEC-1 gene contains 6 exons and 2 promoters with distinct activities. The expression of APOBEC-1 in the rat liver is the result of a promoter located upstream, with tissue-specific exon use and alternate splicing within the 5Ј-untranslated region of APOBEC-1 mRNA encoded by exon 2. In addition to the liver, this promoter also induces APOBEC-1 expression in the spleen, lung, kidney, heart, and skeletal muscle. The promoter located downstream belongs to a new class of TATA-less promoters and is responsible for the abundant expression of APOBEC-1 in the intestine. Mapping of the transcriptional start sites and deletion analysis of the promoter regions by using luciferase as the reporter gene have defined the regulatory elements of both promoters. The downstream, intestine-specific promoter contains a negative regulatory element between Ϫ1100 and Ϫ500, which appears to restrict its activity to the intestine. The upstream, liver-specific promoter of the rat APOBEC-1 gene induces APOBEC-1 expression and editing of apo B mRNA in human hepatoma HuH-7 and Hep G2 cells. Understanding the molecular basis for the liver-specific expression of APOBEC-1 in the rat promises new strategies to induce APOBEC-1 expression in the human liver for the reduction of atherogenic lipoprotein levels by hepatic apo B mRNA editing. (Arterioscler Thromb Vasc Biol. 1998;18:1079-1092.)
A polipoprotein B, the essential protein core component of atherogenic lipoproteins, exists in two forms.
1 Apo B-100, a 512-kDa protein, is the integral structural protein of VLDLs, which are secreted by the liver. 1, 2 After triglyceride hydrolysis, most of the VLDL remnants are rapidly taken up by the liver, but some are further metabolized into LDLs that contain apo B-100 as the only apoprotein.
1,2 Elevated plasma levels of LDL represent a major condition for the development of atherosclerosis and coronary artery disease. 3 The second apo B form, apo B-48, consists of the amino-terminal 48% of the full-length apo B-100 protein and is the essential protein component of chylomicrons secreted by the intestine. 4 The generation of apo B-48 is due to mRNA editing, ie, a specific posttranscriptional base change from C to U in the apo B mRNA that creates a premature translational stop codon (UAA) from a glutamine codon (CAA). [4] [5] [6] In humans and many other mammalian species, apo B mRNA is extensively edited in the intestine, which synthesizes only apo B-48, whereas the apo B mRNA remains completely unedited in the liver, leading to the exclusive synthesis of apo B-100. 7 In some mammals such as the dog, horse, rat, and mouse, apo B mRNA is also edited in the liver, and the hepatic secretion of apo B-48 -containing VLDL is accompanied by low levels of apo B-100 -containing LDL. 7 Thus, editing of apo B mRNA in the liver appears to be a genetic mechanism to limit the plasma levels of atherogenic lipoproteins. 7 Editing of apo B mRNA is mediated by a multicomponent enzyme complex termed apo B mRNA editing enzyme. 4,8 -10 Its catalytic subunit APOBEC-1 (apo B editing catalytic polypeptide 1) is a cytidine deaminase with a novel RNA binding motif. [11] [12] [13] [14] [15] [16] APOBEC-1 requires additional "auxiliary" proteins for efficient apo B mRNA editing. [11] [12] [13] [14] [15] [16] In mice and rats, APOBEC-1 is expressed in many organs, the highest expression being found in the small intestine, spleen, and liver, followed by the kidney, lung, skeletal muscle, and heart. 11, 17 Editing of apo B mRNA in the rat and mouse liver can be modulated by developmental, hormonal, or nutritional stimuli, most of which apparently do not modulate the expression of APOBEC-1. 18 -25 Thus, apo B mRNA editing in the rat or mouse liver is dependent on both the abundance of APOBEC-1 and other trans-acting factors yet to be conclusively identified. 26 -28 In humans and rabbits, which do not edit hepatic apo B mRNA, APOBEC-1 is mainly expressed in the small intestine and, to some extent, in the colon (rabbit) but in no other organ.
14, 29 The lack of APOBEC-1 limits the editing of apo B mRNA in the liver of mammals that do not edit hepatic apo B mRNA.
Adenovirus-mediated expression of APOBEC-1 in the rabbit liver in vivo leads to editing of hepatic apo B mRNA and consequently to a substantial reduction of circulating plasma LDL levels in normal and Watanabe heritable hyperlipidemic rabbits. 30, 31 In mice transgenic for human apo(B) and human apo(a), hepatic overexpression of APOBEC-1 by adenovirus-mediated gene transfer lowers Lp(a) levels in plasma. 32 Thus, induction of apo B mRNA editing in the human liver appears to be a promising genetic approach to reduce elevated plasma levels of the atherogenic LDL or Lp(a). 33 In APOBEC-1 transgenic mice and rabbits, however, in which APOBEC-1 expression was driven by the promoter of the human apo E gene, hepatocellular dysplasia and carcinoma developed in nearly every animal. 34 Naturally, APOBEC-1 can be expressed in the liver of horses, dogs, rats, and mice without obvious oncogenic effects. 7, 11, 17 The molecular basis for the hepatic expression of APOBEC-1 in these mammalian species is therefore of great interest. In the current investigation, the genomic organization of the rat APOBEC-1 gene and its expression pattern were studied. Two distinct promoters induce APOBEC-1 expression in the rat liver and intestine. The upstream, liver-specific promoter of the rat APOBEC-1 gene has the capacity to induce APOBEC-1 expression and apo B mRNA editing in human hepatoma cells.
Methods

RACE and RT-PCR of APOBEC-1 mRNA
Total RNA was prepared from rat liver and intestine by CsCl density gradient ultracentrifugation essentially as described previously. 7, 30 Poly(A) ϩ RNA was prepared from total RNA by using oligo(dT) spin columns (Oligotex) essentially as described by the manufacturer (Qiagen). First-and second-strand cDNA synthesis with subsequent adapter ligation was performed with a commercially available kit (Marathon cDNA amplification kit, Clontech). In brief, first-strand cDNA was synthesized from 1 g poly(A ϩ ) RNA at 42°C for 1 hour by using Moloney murine leukemia virus reverse transcriptase and a modified lock-docking oligo(dT) primer. For second-strand synthesis, the cDNA was incubated for 1.5 hours at 16°C with Escherichia coli DNA polymerase I, E coli DNA ligase, and Rnase H. Subsequently, T4 DNA polymerase was added, and the incubation was continued for 45 minutes. After phenol-chloroform extraction and ethanol precipitation, the double-stranded cDNA was ligated to the provided adapters (Marathon cDNA adapter) at 16°C for 16 hours by using T4 DNA ligase. The 5Ј ends of APOBEC-1 mRNA were amplified from the adapter-ligated cDNA pool by 5Ј RACE-PCR using Advantage KlenTaq-1 polymerase, the adapter-specific primer AP1, and 1 of the following rat APOBEC-1 antisense oligonucleotides: DA113 (ϩ16 to Ϫ3 from ATG: CTGTCTCGGAACT-CATCTT), DA115 (Ϫ4 to Ϫ31 from ATG: GCTCTCTGT-GTCTCTCGACTCCTTCCTC), and DA1115 (Ϫ32 to Ϫ61 from translation start site ATG: GGGAGCTTATGTTGCGGCGATG-GCTGCTGC). Thermal cycling was performed in a Perkin-Elmer DNA thermal cycler 480 using the following touchdown program: 1 minute at 94°C, 5 cycles (94°C for 30 seconds, 72°C for 4 minutes), 5 cycles (94°C for 30 seconds, 70°C for 4 minutes), and 27 cycles (94°C for 20 seconds, 67°C for 4 minutes). The products of the 5Ј RACE were analyzed on 2% agarose gels stained with ethidium bromide. The generated bands were excised from the gel, purified on QIAuick columns (Qiagen), and ligated into the pGEM-T vector (Promega). Plasmid DNA of individual recombinant clones was sequenced on an automated sequencer using the ABI PRISM dye terminator cycle sequencing ready reaction kit (Perkin-Elmer) with a vector-specific primer. RT-PCR of APOBEC-1 mRNA from rat liver and intestine was performed by using the antisense primer APOBEC III (CAGATGGGGGTACCTTGGCCAATGAGC, ϩ519 to ϩ493) and the sense primer APOBEC I (GAGGAAGGAGTCCAGAGA-CACAGAGAGC, Ϫ31 to Ϫ4 in the 5Ј UTR) or the antisense primer APOBEC V (TCCCAGAAGTCATTTCAACCCTGT, ϩ699 to ϩ670, spanning the stop codon TGA) and the sense primer APOBEC IV (GCTCATTGGCCAAGGTACCCCCATCTG, ϩ493 to ϩ519) essentially as described.
30
Isolation and Characterization of Rat APOBEC-1 Genomic Clones
A rat genomic EMBL-3 SP6/T7 library, prepared from adult male Sprague-Dawley rats, was purchased from Clontech (catalog No. RL1022). Recombinant phages (4ϫ10 6 )were screened by hybridization with a full-length APOBEC-1 cDNA as described previously. 30 One hybridizing -clone was plaque purified for 3 rounds. Phage particles were purified from plaque lysate by using a rabbit polyclonal antibody, and phage DNA was purified on glass-milk (Lambda-Trap Plus, Clontech). The -DNA was digested with SacI, and the resulting restriction fragments of 6.2, 4.0, 3.8, and 1.2 kb were cloned in SacI-digested pT7/T3 (Pharmacia). The resulting recombinant plasmids were hybridized with rat APOBEC-1 oligonucleotides to align them to the cDNA sequence. The exon-intron junctions were sequenced by using the ABI PRISM dye terminator cycle sequencing ready reaction kit (Perkin-Elmer) with the following primers: DA113 (3Ј splice acceptor in exon 2); APOBEC I (5Ј splice donor in exon 2); DA17 (TTCCCACATGATTTGTAGATTTGGGA GACT, sense primer in intron 2 for sequencing exon 3 and its junctions); APOBEC XIV (AGTCCTTGCCGATTTCGAGGATCT-GCG TG, antisense ϩ392 to ϩ363 for the 3Ј splice acceptor site of exon 4); APOBEC XVIII (AGCCGATACCCCCATGTAACTCT-GTTT, sense ϩ313 to ϩ339 for the 5Ј splice donor site in exon 4); APOBEC III (for the 3Ј splice acceptor site in exon 5); APOBEC IV (for the 5Ј splice donor site in exon 5); APOBEC V (for the 3Ј splice acceptor site in exon 6), APOBEC XII (CACATCCTGTGGGCCA-CAGGGTTGAAATGA, sense ϩ661 to ϩ690 for sequencing exon 6); and APOBEC XIIa [ATCCGGCCTGTCATTCCTGGGTAG-CATGCTA, sense; 3Ј position of poly(A) site for sequencing the 3Ј end of the 6.2-kb SacI fragment, ie, 3Ј end of the 15.2-kb genomic fragment]. The 5Ј flanking region of exon 1, the 5Ј splice donor site of exon 1, and the 5Ј flanking region of exon 2 were isolated by PCR "walking" using the commercially available PromoterFinder DNA walking kit (Clontech) with Clontech's Advantage polymerase mix exactly as recommended. The following gene-specific primers were
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APOBEC-1 ϭ apo B editing catalytic polypeptide 1 CMV ϭ cytomegalovirus ␤-gal ϭ ␤-galactosidase MED ϭ multiple start site element downstream PCR ϭ polymerase chain reaction RACE ϭ rapid amplification of cDNA ends RT ϭ reverse transcription SV ϭ simian virus UTR ϭ untranslated region used: for amplification of the 5Ј flanking region of exon 1, DAex13 for the primary PCR (TTCTTCCTGATCTAATTTAAGGGAG-GAGC, antisense exon 1, Ϫ158 to Ϫ187 from ATG) and DAex15 for the nested PCR (GCCTTTCTGCCTTCAAAATCC AACTCT-CAT, antisense exon 1, Ϫ188 to Ϫ217 from ATG); for amplification of the 5Ј splice donor site of exon 1 and intron 1, DAex1S51 for the primary PCR (CCTACTCCCGCTAC AGAACCACTG TGCCC, sense in exon 1, Ϫ246 to Ϫ218 from ATG) and DAex1S2 (AT-GAGAGTTGGATTTTGAAGGCAGAAAGGC, sense in exon 1, Ϫ217 to Ϫ188 from ATG); for amplification of the 5Ј flanking region of exon 2, DA113 for primary PCR and DA115 for nested PCR; and for walking within intron 1 toward exon 1, DA43 (AGTGTATTAATGA GACTAAGAACTCACAA) for primary PCR and DA45 (CAGGGAACCCTAAATCCTCTG TAA-CACTCT) for nested PCR. The primary PCR was performed in a Perkin-Elmer DNA thermal cycler 480 using the following 2-step cycle parameters: 7 cycles (94°C for 25 seconds, 72°C for 4 minutes) and 32 cycles (94°C for 25 seconds, 67°C for 4 minutes), followed by an additional 4 minutes at 67°C. For nested PCR the following 2-step cycle parameters were used: 5 cycles (94°C for 25 seconds, 72°C for 4 minutes) and 22 cycles (94°C for 25 seconds, 67°C for 4 minutes), followed by an additional 4 minutes at 67°C. The amplified genomic fragments were isolated from 0.8% agarose gels and cloned into the pGEM-T vector. A portion (2.5 kb) of the 5Ј flanking region of exon 1, the exon-intron junction of exon 1, and 2.0 kb of the 5Ј flanking region of exon 2 were sequenced by using the ABI PRISM dye terminator cycle sequencing ready reaction kit (PerkinElmer). For sequencing of the 5Ј flanking region of exon 1, the following primers were used: DAex17 (GCCAAGTTACCCCAC-TAATTAGGATTTAGGG) and DAex16 (CCCAGGAGCA GTGC-CGCATCCACTTTCTTC). For sequencing of the 5Ј flanking region of exon 2, the following primers were synthesized: DA117 (CTC-CCTCAAGGTCTAAGTCTCCCACTAG GG) and DA23 (ACT-CACTATA GGGCTCGAGCGGC).
Primer Extension Analysis of Transcriptional Start Sites in APOBEC-1 mRNA From Rat Liver and Intestine
Five micrograms of total RNA from rat liver and intestine or tRNA was denatured for 10 minutes at 70°C, annealed to radiolabeled oligonucleotide DAex15 or DA115 for 30 minutes at 42°C, and extended with 10 U avian myeloblastosis reverse transcriptase for 60 minutes. After addition of 4 U RNase A, the primer extension products were separated on an 8% polyacrylamide-7 mol/L urea sequencing gel. The DNA sequence of exon 1 and exon 2 was determined by using Sequenase (Amersham) and radiolabeled oligonucleotides DAex15 and DA115. The sequencing reactions were separated on the same sequencing gel along with the primer extension products to map the transcriptional start sites.
RNase Protection Assay of Transcriptional Start Sites and Splice Variants of APOBEC-1 mRNA in Rat Organs
A rat genomic DNA fragment consisting of 158 nucleotides spanning 68 bp of the upstream promoter region and 90 bp of transcribed sequences of exon 1 was amplified by PCR with the oligonucleotides MS5 (GCGAGCTCGCCTGACAGCAA ACCCCAGCCA, Ϫ68 to Ϫ39 from the transcriptional start site in exon 1) and DAex15. A rat genomic fragment of 248 nucleotides spanning 94 bp of the promoter region of exon 2 and 154 bp of the transcribed sequences of exon 2 was amplified by PCR with the oligonucleotides MS16 (GC-GAGCTCTCTCCAGGGAGGACG GAAATC, Ϫ166 to Ϫ148 from the transcriptional start site in exon 2) and DA115. The two PCR products were cloned into the pGEM-T Easy vector (Promega) and sequenced to identify their orientation. Two micrograms of plasmid DNA linearized with EcoRI was transcribed for 30 minutes at 37°C with 5 U T7 RNA polymerase in the presence of 500 mol/L each ATP, GTP, and CTP and 12 mol/L of [␣- 32 P]UTP (specific activity, 800 Ci/mmol) to generate an antisense transcript of 228 bases of exon 1 and of 322 bases of exon 2. After digestion of plasmid DNA with 10 U RNase-free DNase I (Pharmacia) for 15 minutes at 37°C, the RNA transcripts were purified by phenol-chloroform extraction and S-300 microspin columns (Pharmacia). Total RNA was purified from 10 rat organs (liver, intestine, stomach, colon, spleen, lung, kidney, brain, heart, and skeletal muscle) by using Tri-Reagent and following the manufacturer's (Molecular Research Center Inc) protocol exactly. Fifty micrograms of total RNA from each organ was coprecipitated with 4ϫ10 4 counts per minute of ␣-32 P-labeled RNA probe and hybridized for 18 hours at 42°C in 20 L of solution A of the ribonuclease protection assay II kit (Ambion Inc). After 200 L of solution B containing 1:50 -diluted RNase A and RNase T1 was added, the incubation was continued for 30 minutes at 37°C. After addition of 300 L of solution D, the undigested RNA fragments were precipitated for 30 minutes at Ϫ20°C and subsequently resolved on a 6% denaturing polyacrylamide sequencing gel. A DNA molecular-weight marker (Boehringer Mannheim 100-bp ladder) and oligonucleotide DD3 with a length of 35 bases, 30 which had been labeled by using T4 polynucleotide kinase and [␥-
32 P]ATP, were analyzed on the same gel. The semilogarithmic graph of molecular weight versus length of migration gave a straight line, from which the approximate lengths of the protected RNA fragments were deduced. For improved precipitation of smaller protected fragments, 250 L of 100% ethanol was added to the precipitation mix, and the precipitation was extended to 1 hour at Ϫ20°C.
Generation of APOBEC-1 Promoter-Luciferase Reporter Constructs: 5 Flanking Region of Exon 1
Two fragments of the 5Ј flanking region of exon 1 of Ϸ2.5 and 2.0 kb that had been isolated by genomic PCR walking and cloned into the pGEM-T vector were isolated by SalI digestion and cloned into the XhoI site of pGL3-basic. The resulting promoter constructs, designated LP1 and LP2, were sequenced to confirm their orientation. LP1 extended from nucleotide position Ϫ2535 from the transcriptional start site to ϩ92 (corresponding to position Ϫ188 from the translational start site ATG) and LP2 from Ϫ2089 to ϩ92. Serial deletions were constructed by PCR by using the universal downstream oligonucleotide MS1 (CACAAGCTTCCTGACCA-GAGAAAGCTGAGG, APOBEC-1 5Ј UTR antisense; Ϫ252 to Ϫ279 from translational start site ATG) and the following upstream primers: for LP3, MS2 (GAAGTCGACTTCCATTTTGATAGAG-GTCAG, position Ϫ930 to Ϫ901 from the transcriptional start site); for LP4, MS3 (ACCGTCGACTGTTTTTCAGTCA TCTGGACT, position Ϫ501 to Ϫ472); for LP5, MS4 (AAGCGGCTGGATGTC-GACAACA ACAATAAC, Ϫ155 to Ϫ126); for LP6, MS5 (GC-GAGCTCGCCTGACAGCAAACCC CAGCCA, Ϫ68 to Ϫ39); and for LP7, MS6 (GCGAGCTCTTAAAGCCGAACCAGCAA, Ϫ25 to ϩ1). The resulting promoter fragments were digested with HindIII and SalI (LP3 to LP5) or SacI (LP6 and LP7) and cloned into the respective sites of pGL3-basic. The generated constructs were sequenced to confirm the orientation and sequence. For the 5Ј flanking region of exon 2, Ϸ2.0 kb of the 5Ј flanking region of exon 2, which had been isolated by genomic PCR walking and cloned into the pGEM-T vector, was cloned into the XhoI site of pGL3-basic. The resulting construct, designated IP1, was sequenced to confirm its orientation and sequence. IP1 extended from nucleotide position Ϫ2070 from the transcriptional start site to ϩ81 (corresponding to position Ϫ4 in the 5Ј UTR from the translational start site ATG). Serial deletions were constructed by PCR by using the universal downstream oligonucleotide MS11 (TGTAAGCTTCCTTCCTCGG-GAGCTTATG, APOBEC-1 5Ј UTR antisense; Ϫ23 to Ϫ42 from the translational start site ATG, corresponding to ϩ44 to ϩ63 from the transcriptional start site) and the following upstream primers: for IP2, MS12 (TTTGTCGACTGATGATTGGTGTGGGAGTGC, Ϫ1173 to Ϫ1144 from the transcriptional start site); for IP3, MS13 (GAAGTCGACCCAACGTTCTGGCAACAGAAG, Ϫ587 to Ϫ558 from the transcriptional start site); for IP4, MS14 (CCTGTCGACT-TCTTAGATATAGGAGCT, Ϫ324 to Ϫ298); for IP5, MS15 (GC-GAGCTCTGGAATTTAACATCATCGATG, Ϫ311 to Ϫ293); for IP6, MS16 (GCGAGCTCTCTCC AGGGAGGACGGAAATC, Ϫ166 to Ϫ148); and for IP7, MS17 (TGGAGCTCAGGAAT GAGTCATCCTGT, Ϫ57 to Ϫ32). The resulting fragments were digested with HindIII and SalI (IP2 to IP4) or SacI (IP5 to IP7) and cloned into pGL3-basic. The generated constructs were sequenced in their entirety to confirm orientation and sequence. For IP⌬ mutants, the fragment Ϫ2070 to Ϫ1145 and the fragment Ϫ2070 to Ϫ 558 of the 5Ј flanking region of exon 2 were amplified by PCR using a vector-specific SP6 primer (ATTTAGGTGACACTATA-GAATACTCAAG) and the antisense downstream primer MS22 (GCGAGCTCGCACTCCCACACCAATCATCAGTC, Ϫ1145 to Ϫ1173 from the transcriptional start site in exon 2) or MS23 (GCGAGCTCTCTTCTGTTGCCAGAACGTTGGG, Ϫ557 to Ϫ582 from the transcriptional start site in exon 2). The 2 PCR products were digested with SacI and fused directly in front of the promoter region of the construct IP5 by using the unique SacI site. The proper orientation of insertion was determined by DNA sequencing. These two constructs were designated IP⌬1144 -216 and IP⌬556 -216. For IPϫLP mutants, the fragments Ϫ1167 to Ϫ266, Ϫ581 to Ϫ266, and Ϫ318 to Ϫ266 of the 5Ј flanking region of exon 2 were amplified by PCR using the universal antisense downstream primer MS22 (GCGAGCTCGCACTCCCACACCAATCAT-CAGTC, Ϫ266 to Ϫ289 from the transcriptional start site in exon 2) and either MS12, MS13, or MS14. The resulting PCR products were cloned into the pGEM-T easy vector. Fragments of the proper orientation were excised from the vector with SacI and NheI, gel purified, and ligated in front of the promoter fragment of LP5 by using the unique sites SacI and NheI in LP5. The resulting promoter constructs were designated IP(1167-266)-LP5, IP(581-266)-LP5, and IP(318 -266)-LP5.
Transfection of Promoter Constructs
Human colonic carcinoma Caco-2 cells, kindly provided by Dr C. Courtelle, London, UK, were grown in Dulbecco's modified Eagle's medium containing 2 mmol/L glutamine and 20% FCS. Mouse fibroblast NIH/3T3 cells, kindly provided by Dr M. Spiess, Basel, Switzerland, and the human hepatoma HuH-7 cells, kindly provided by Dr J. Chowdhury, New York, NY, were grown in Dulbecco's modified Eagle's medium containing 2 mmol/L glutamine and 10% FCS. Cells (5ϫ10 5 ) were seeded per well of a 6-well plate. After 24 hours the cells were cotransfected with 2 g/mL reporter plasmid and 0.1 g/mL CMV-␤-gal by using the Lipofectin procedure (GIBCO) essentially as described. 30 In brief, cells were incubated for 6 hours with 1 mL of Optimem-1 (GIBCO) containing 2 g reporter plasmid, 0.1 g CMV-␤-gal as the internal-standard plasmid, and 15 L Lipofectin. Subsequently, cells were grown in normal medium for 48 hours, washed twice with PBS, and lysed in 250 L of reporter lysis buffer (Promega). The cell lysate was freeze-thawed and centrifuged in a Microfuge. After addition of 50 L luciferase assay buffer (Promega), luciferase activity was determined in 10 L of soluble cell extract by using a luminometer (Berthold Microlumat LB 96 P). ␤-Gal activity was measured by luminometry using the Galacto-Light reporter gene assay for ␤-gal (Tropix, BL300G). The luciferase activity of each well was normalized to ␤-gal activity. All assays were performed in triplicate. At least 3 independent experiments, each in triplicate assay, were performed for each determination. The meanϮSEM was calculated and expressed as relative luciferase activity, based on the luciferase activity of cells transfected with the promoterless plasmid pGL3-basic and the internalstandard plasmid CMV-␤-gal.
Construction of an APOBEC-1 Minigene
The XbaI-BamHI fragment of pSVL-APOBEC-1 30 containing the open reading frame of APOBEC-1 was cloned into the XbaI-BamHI site of pT7T3 (Pharmacia). Subsequently, the BamHI fragment of pSVK3 (Pharmacia), which contains the SV40 small T-antigen splice site and the SV40 early poly(A) site, was ligated into the BamHI site. Subsequently, the SalI fragment of LP1 containing 2.5 kb of the 5Ј flanking region of exon 1 was ligated into the SalI site. The orientation of the promoter fragment was confirmed by DNA sequencing. The resulting plasmid p-APOBEC-1 contains 2.5 kb of the 5Ј flanking region of exon 1, the complete open reading frame of APOBEC-1 followed by the SV40 small T-antigen splice site, and the SV40 early poly(A) site in the plasmid backbone of pT7T3. pSVL-APOBEC-1 and p-APOBEC-1 were transfected in human hepatoma HuH-7 cells and Hep G2 cells essentially as described. 30 Apo B mRNA was amplified by RT-PCR and assayed for editing by primer extension analysis essentially as described.
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Results
RACE of APOBEC-1 mRNA From Rat Liver and Intestine
The 5Ј UTR of APOBEC-1 mRNA from liver and intestine was amplified by 5Ј RACE. Two major bands of Ϸ260 and 210 bp were generated from hepatic APOBEC-1 mRNA by using the antisense oligonucleotide DA1115 ( Figure 1A , lane 1). 5Ј RACE of intestinal APOBEC-1 mRNA using the antisense oligonucleotide DA113 resulted in 3 bands of Ϸ120, 100, and 80 bp ( Figure 1A , lane 2). Control 5Ј RACE without RT did not generate any product ( Figure 1A, lanes 3  and 4) . The 5Ј RACE products from liver and intestine were purified from a 2% agarose gel and cloned. The inserts of at least 6 individual recombinant clones for each purified 5Ј RACE product were sequenced. The 5Ј UTR of APOBEC-1 Figure 1 . 5Ј RACE of APOBEC-1 mRNA from rat liver and intestine. 5Ј RACE of APOBEC-1 mRNA was performed using total RNA from rat liver and intestine. Resulting 5Ј RACE products and their controls without reverse transcriptase were separated on 2% agarose gel. Photograph of ethidium bromidestained gel is shown together with a synopsis of nucleotide sequences of the various 5Ј RACE products. The following symbols were used to indicate 5Ј ends of the 5Ј RACE products and splice variants of hepatic APOBEC-1 mRNA: *5Ј end of 5Ј RACE of APOBEC-1 from rat liver; **5Ј end of 5Ј RACE of APOBEC-1 from rat intestine (120-bp product); ***5Ј end of 5Ј RACE of APOBEC-1 from rat intestine (100-bp product); ****5Ј end of 5Ј RACE of APOBEC-1 from rat intestine (80-bp product), boxed insertion in the longer 5Ј RACE product of APOBEC-1 mRNA from rat liver; ϩ proximal 3Ј splice acceptor site of exon 2; and ϩϩ distal 3Ј splice acceptor site of exon 2, underlined common 5Ј UTR of APOBEC-1 mRNA in rat liver and intestine ATG translational start codon of APOBEC-1.
mRNA from rat liver contained unique sequences at its 5Ј end that were lacking in the 5Ј UTR of rat intestinal APOBEC-1 mRNA ( Figure 1B) . The 5Ј ends of both the 260-and the 210-bp 5Ј RACE products were identical. Fifteen recombinant clones of the 5Ј RACE products from rat liver ended within a region of 5 nucleotides ( Figure 1B, one asterisk) . The larger 5Ј RACE product of APOBEC-1 mRNA from rat liver contained an additional insertion of 51 nucleotides in comparison with the smaller 5Ј RACE product from rat liver ( Figure 1B, boxed sequence) . The 5Ј RACE products of APOBEC-1 mRNA from rat intestine contained as many as 85 nucleotides of the most 3Ј region of the hepatic 5Ј UTR of APOBEC-1 ( Figure 1B, underlined sequence) . The three 5Ј RACE products of APOBEC-1 mRNA from rat intestine differed by Ϸ20 nucleotides each at their 5Ј ends ( Figure 1B ; 5Ј ends of the products are indicated by 2, 3, and 4 asterisks). Similar results were obtained in 3 additional independent 5Ј RACE reactions using the primer DA115 in addition to DA1115 and DA113. RT-PCR of rat intestinal total RNA was performed using the primers APOBEC III and APOBEC I, or APOBEC V and APOBEC IV. These 2 RT-PCR products span the open reading frame of APOBEC-1. Both RT-PCRs generated a single major band that was isolated and cloned. DNA sequencing confirmed the rat APOBEC-1 cDNA sequence in rat liver and intestine as reported by Teng et al, 11 without evidence for additional alternate processing of APOBEC-1 mRNA.
Characterization of the Rat APOBEC-1 Gene
A -clone was isolated from an EMBL3 SP6/T7 rat genomic library that encoded a 15.2-kb genomic fragment of the rat APOBEC-1 gene (Figure 2A ). Digestion with SacI generated 4 restriction fragments of 6.2, 4.0, 3.8, and 1.2 kb that were cloned and aligned with the APOBEC-1 cDNA sequence. The exon-intron junctions were determined by DNA sequencing. The isolated genomic fragment contained 5 exons and 0.7 kb of the 5Ј flanking region of the most 5Ј-located exon. This exon contained the translational start site for APOBEC-1 and the common 5Ј UTR of APOBEC-1 mRNA from both rat liver and intestine. The additional sequences of the 5Ј UTR of rat hepatic APOBEC-1 mRNA, however, could not be aligned with this 15.2-kb rat genomic fragment. The 5Ј flanking region of the 5Ј UTR of APOBEC-1 from rat liver and its 5Ј splice donor site were isolated by PCR walking. The rat APOBEC-1 gene contains an additional exon in the 5Ј position of exon 2, resulting in a total of 6 exons. Figure 2A illustrates the genomic organization of the rat APOBEC-1 gene, the isolated -clone, its 4 SacI fragments, and the 4 PCR walks that span the 5Ј end of the rat APOBEC-1 gene. In Figure 2B , the exon-intron organization and the exon- 3A). Within the 5Ј flanking region of exon 1, a variety of consensus sequences for potential interactions with transacting factors were identified by computer alignment and are illustrated in Figure 3A . Notably, motifs for hepatic transcription factors were identified: liver activator protein at Ϫ964 to Ϫ956, HNF3/AP1 at Ϫ706 to Ϫ698, and C/EBP at Ϫ303 to Ϫ299 and Ϫ837 to Ϫ833. The 5Ј flanking region of exon 2 contains two CCACT motifs as variant CAT boxes at Ϫ131 to Ϫ126 and Ϫ263 to Ϫ259. Within the typical distance of the transcriptional start site (20 to 30 nucleotides), a classic TATA box, however, is lacking. A putative TATA box, however, is located upstream at position Ϫ307 to Ϫ304. A conserved downstream element of many TATA-less promoters, the MED-1 motif GCTCCC, 35 is located within exon 2 at ϩ49 to ϩ53 from the transcriptional start site. The consensus sequences for potential trans-acting factors within the 5Ј flanking region of exon 2 as well as the MED-1 sequence in exon 2 are illustrated ( Figure 3B ).
Primer Extension Analysis of the Transcriptional Start Sites for APOBEC-1 in Rat Liver and Intestine
Using radiolabeled antisense oligonucleotide DAex15, which corresponds to the Ϫ188 to Ϫ217 region of the 5Ј UTR of rat hepatic APOBEC-1 encoded by exon 1, we generated a discrete primer extension product exclusively from total hepatic RNA but not from total intestinal RNA or tRNA control ( Figure 4A ). The DNA sequence analysis of genomic DNA with radiolabeled DAex15 was separated side by side along with the primer extension assay on the same sequencing gel ( Figure 4A ). By alignment with the genomic sequence, the putative transcriptional start site of APOBEC-1 mRNA in rat liver was mapped to nucleotide position Ϫ279 from the translational start codon ATG ( Figure 4A and 4B ). This putative transcriptional start site maps 22 nucleotides upstream from the 5Ј RACE of rat hepatic APOBEC-1 mRNA that ended at nucleotide position Ϫ257 ( Figure 4B ). Using radiolabeled oligonucleotide DA115, which corresponds to the Ϫ4 to Ϫ31 region of the 5Ј UTR of APOBEC-1 encoded by exon 2, we generated a major primer extension product from intestinal RNA only and not from hepatic RNA or tRNA ( Figure 4C) . A minor extension product was visible in both intestinal and hepatic RNA but not in the tRNA control. Alignment of the major extension product from rat intestinal APOBEC-1 mRNA with the DNA sequence of exon 2 mapped the putative transcriptional start site for APOBEC-1 mRNA in rat intestine to nucleotide position Ϫ77 from ATG ( Figure 4C and 4D) . In comparison, the 2 larger 5Ј RACE products of APOBEC-1 mRNA from rat intestine extended to nucleotide positions Ϫ85 and Ϫ64 from ATG, respectively ( Figure 4D ).
Ribonuclease Protection Assay for Transcriptional Start Sites of APOBEC-1 in Various Rat Organs
The transcriptional start sites of APOBEC-1 in exons 1 and 2 and the splice sites in exon 2 were further characterized by ribonuclease protection assay. An antisense RNA probe of exon 1 was transcribed containing a 158-bp genomic fragment that spans approximately the distal 70 bp of the promoter and 90 bp of the transcribed sequences of exon 1. This transcript has a length of 232 nucleotides owing to transcribed vector sequences ( Figure 5A ). With the use of this probe, an RNA fragment of Ϸ90 bases was protected in total RNA from the liver, intestine, colon, spleen, lung, kidney, heart, and skeletal muscle but not in the stomach or brain ( Figure 5A) . The strongest signals were generated in the spleen, lung, and kidney. In the liver and intestine, relatively weak protection was observed ( Figure 5A ). With the use of total RNA from the heart, the protected fragment was slightly larger ( Figure 5A ). No fragments of these sizes were protected when an equal amount of yeast total RNA was used ( Figure 5A ). However, 2 large bands were generated in the same quantities in both yeast total RNA and RNA from all organs tested. Increased RNase concentration or extended digestion time did not diminish these 2 large fragments in yeast or rat RNA. Identical results were obtained in 4 independent ribonuclease protection assays using various preparations of this antisense RNA probe encoded by exon 1 of rat APOBEC-1.
For exon 2, an antisense RNA probe was synthesized in vitro containing Ϸ94 bp of the distal promoter region of exon 2 and 154 bp of transcribed sequences of exon 2. Together with the transcribed multiple cloning site, the transcript has a length of 322 nucleotides. The 248 nucleotides of exon 2 contain both the proximal and distal splice acceptor sites as well as the various transcriptional start sites within exon 2, as deduced from 5Ј RACE. With the use of this antisense RNA probe, several fragments were protected in total RNA from the liver, intestine, spleen, lung, kidney, and to a lesser degree, the stomach, colon, heart, and skeletal muscle ( Figure 5B ). The RNA fragment of 154 nucleotides corresponds to the major proximal splice acceptor site of exon 2. The fragment of Ϸ144 nucleotides appears to be due to a minor proximal splice acceptor site in exon 2. The fragment of 103 nucleotides represents the distal splice acceptor site in exon 2. These 3 protected fragments that represent splice variants of APOBEC-1 transcripts initiated in exon 1 are present in the spleen, liver, lung, and to a minor extent, the colon, kidney, heart, and skeletal muscle; however, they are abundant in the intestine, where the exon 1-specific antisense transcript was hardly protected (Figure 5A and 5B). In the intestine, an additional RNA fragment of Ϸ80 nucleotides was protected ( Figure 5B ). Moreover, a very faint band of Ϸ250 nucleotides was specifically protected in the intestine ( Figure 5B ). By improved precipitation of smaller RNA fragments and separation on an 8% polyacrylamide sequencing gel, 2 additional protected RNA fragments of 60 and 40 nucleotides, respectively, could be demonstrated exclusively in the intestine ( Figure 5C ). The 3 fragments of 80, 60, and 40 nucleotides correspond to the 3 intestinal transcriptional start sites as demonstrated by 5Ј RACE ( Figure 1A and 1B) . No protected fragment was generated when yeast total RNA was used ( Figure 5B and 5C). Identical results, as shown in Figure 5B and 5C, were obtained in 3 other independent ribonuclease protection assays.
Functional Characterization of the 5 Flanking Regions of Exons 1 and 2
The promoter activities of the 5Ј flanking regions of exons 1 and 2 were investigated in transfection studies with luciferase as a heterologous reporter. Serial deletions of the 5Ј flanking regions of exons 1 and 2 were constructed by PCR, cloned into the pGL3-basic vector, and sequenced. The constructs of the 5Ј flanking region of exon 1 were designated LP1 to LP7. LP1 and LP2 ended at nucleotide position ϩ92 from the transcriptional start site, and LP3 to LP7 ended at nucleotide position ϩ24 from the transcriptional start site. The constructs of the 5Ј flanking region of exon 2, designated IP1 to IP7, extended to nucleotide position ϩ81 (IP1) or ϩ63 (IP2 to IP7) from the intestinal transcriptional start site and therefore contained the MED-1 motif that is located at position ϩ49 to ϩ53.
The results of transfection studies for these promoter constructs are illustrated in Figure 6 . LP1 (Ϫ2535 to ϩ92) exerted a 2.5-fold stronger promoter activity in HuH-7 cells and a 3-fold stronger promoter activity in NIH/3T3 cells compared with Caco-2 cells ( Figure 5A ). LP2 (Ϫ2089 to ϩ92) and LP3 (Ϫ924 to ϩ28) showed a gradual loss of promoter activity in all 3 cell lines. LP4 (Ϫ495 to ϩ28) and LP5 (Ϫ140 to ϩ28) demonstrated an increase in promoter strength in all 3 cell lines. LP5, Figure 4 . Primer extension analysis for determination of transcriptional start sites. A, Transcriptional start sites within exon 1 were determined by primer extension analysis in total RNA from rat liver and intestine and tRNA control by using radiolabeled oligonucleotide DAex15. DNA sequence analysis of exon 1, determined from cloned rat genomic DNA by using radiolabeled DAex15, was separated on 8% polyacrylamide-7 mol/L urea sequencing gel side by side with primer extension products. DNA sequence of exon 1 is shown as the complementary sense sequence. B, Transcriptional start sites as determined by 5Ј RACE and primer extension analysis are illustrated together with genomic sequence of exon 1. C, Transcriptional start sites within exon 2 were determined by primer extension analysis in total RNA from rat liver and intestine and tRNA control by using radiolabeled oligonucleotide DA115. DNA sequence analysis of exon 2, determined from cloned rat genomic DNA using radiolabeled oligonucleotide DA115, was separated on 8% polyacrylamide-7 mol/L urea sequencing gel side by side with primer extension products. DNA sequence of exon 2 is shown as the complementary sense sequence. D, Transcriptional start sites as determined by 5Ј RACE and primer extension analysis are illustrated together with genomic sequence of exon 2.
with slightly more promoter activity than LP1, still contained the TAAA motif at Ϫ16 to Ϫ13 as the presumptive variant TATA box and the CACT motif at Ϫ101 to Ϫ98 as the putative CAT box. LP6 (Ϫ63 to ϩ28), which lost the putative CAT box at Ϫ101 to Ϫ98, had strongly reduced promoter activity. LP7 (Ϫ20 to ϩ28), in which the putative TATA box at Ϫ16 to Ϫ13 was the only remaining promoter element, lost any promoter activity and was similar to the promoterless control construct pGL3-basic. The construct LP1, in which the promoter fragment of LP1 was inserted in the opposite direction in pGL3-basic, exhibited less relative luciferase activity than did pGL3-basic (data not shown).
In contrast, IP1 extending from position Ϫ2070 of the transcriptional start site of APOBEC-1 mRNA in rat intestine 32 P]UTP from a genomic DNA fragment that was generated by PCR with oligonucleotides MS5 and DAex15 and which spans the distal 70 bp of the promoter region and 90 bp of transcribed sequences of exon 1. This antisense RNA (4ϫ10 4 cpm) was hybridized for 18 hours at 42°C with 50 g of yeast total RNA or 50 g total RNA from rat organs (liver, intestine, stomach, colon, spleen, lung, kidney, brain, heart, or muscle). Subsequently, RNA was digested in buffer B with RNase A and RNase T1 using a commercially available RNase protection assay kit. Protected RNA fragments were resolved on denaturing 6% polyacrylamide sequencing gel. As a control for integrity of the RNA probe, radiolabeled probe was hybridized with 50 g of yeast total RNA and incubated in buffer B without addition of RNases. Portion (1/50) of this RNA control was loaded onto the gel. After electrophoresis, the gel was dried under vacuum and exposed to autoradiography. Representative autoradiogram is shown together with an illustration of RNA antisense probe and protected fragment. Migration of kinased DNA marker and approximate length of protected fragment are indicated. B and C, For exon 2, its antisense RNA was synthesized in vitro in the presence of 12 mol/L [␣-32 P]UTP from a genomic DNA fragment which was generated by PCR with oligonucleotides MS16 and DA115 and which spans 94 bp of the promoter region of exon 2 and 154 bp of transcribed sequences of exon 2. This antisense RNA (4ϫ10 4 cpm) was hybridized for 18 hours at 42°C with 50 g of yeast total RNA or 50 g total RNA from rat organs (liver, intestine, stomach, colon, spleen, lung, kidney, brain, heart, or muscle). RNA was digested in buffer B with RNase A and RNase T1 using a commercially available RNase protection assay kit. After precipitation, protected RNA fragments were resolved on denaturing 6% polyacrylamide sequencing gel. As a control for integrity of the RNA probe, radiolabeled probe was hybridized with 50 g of yeast total RNA and incubated in buffer B without addition of RNases. Portion (1/50) of this control RNA probe was loaded onto the gel. The dried gel was exposed to autoradiography. Representative autoradiogram is shown together with an illustration of RNA antisense probe and protected fragments. Migration of kinased DNA marker and approximate lengths of protected fragments are indicated (B). For improved precipitation of smaller fragments, RNA was precipitated in 95% ethanol, and protected fragments were resolved on denaturing 8% polyacrylamide sequencing gel (C). Representative autoradiogram is shown together with an illustration of RNA antisense probe and protected fragments corresponding to the 3 distal transcriptional start sites in exon 2. Migration of kinased DNA marker and approximate lengths of protected fragments are indicated. Figure 6 . Transfection of APOBEC-1 promoter-luciferase reporter constructs in HuH-7, Caco-2, and NIH/3T3 cells. A, 5Ј Flanking region of exon 1 was truncated from the 5Ј end by PCR and cloned into promoterless construct pGL3-basic to generate constructs LP1 to LP7. B, 5Ј Flanking region of exon 2 was truncated from 5Ј end by PCR and cloned into promoterless construct pGL3-basic to generate constructs IP1 to IP7. Lengths and positions of various promoter constructs are illustrated. C, Constructs IP⌬1144 -216 and IP⌬556 -216 were generated by ligating fragments Ϫ1144 to Ϫ216 and Ϫ556 to Ϫ216 of the 5Ј-flanking region of exon 2 (IP) to promoter construct IP5. D, Crossover mutants IP(1167-266)-LP5, IP(581-266)-LP5, and IP(318 -266)-LP5 were generated by ligating regions Ϫ1167 to Ϫ266, Ϫ581 to Ϫ266, and Ϫ318 to Ϫ266 of the 5Ј flanking region of exon 2 (IP) to promoter construct LP5. All constructs were transfected into HuH-7, Caco-2, and NIH/3T3 cells together with CMV-␤-gal. After 48 hours activities of luciferase and ␤-gal were determined by luminometry. Activity of luciferase was normalized for activity of ␤-gal and expressed as relative luciferase activity based on activity of promoterless construct pGL3-basic, to which the value of 1.0 was assigned. MeanϮSEM of at least 3 independent experiments in triplicate assay each are given. Values in C and D represent meanϮSEM of 4 additional independent determinations in triplicate assay each, even for constructs IP1, IP5, and LP5.
to position ϩ81 (corresponding to position Ϫ4 in the 5Ј UTR from the translational start codon ATG) exhibited an Ϸ4-fold higher promoter activity in human colonic carcinoma Caco-2 cells than in HuH-7 cells ( Figure 6B) . Truncations of the 5Ј flanking region of exon 2 in IP2 (Ϫ1167 to ϩ63), IP3 (Ϫ581 to ϩ63), and IP4 (Ϫ318 to ϩ63) had no major effect on promoter activity in Caco-2 or HuH-7 cells. In NIH/3T3 cells, all constructs (IP1 to IP7) had very low promoter activities (Ͻ5), close to the activity of the promoterless construct pGL3-basic. In IP5 (Ϫ216 to ϩ63) and IP6 (Ϫ161 to ϩ63), a 2-fold increase in promoter activity was observed in Caco-2 cells and a 5-fold increase in HuH-7 cells compared with the effect of IP1. The shortest construct IP7 (Ϫ52 to ϩ63) demonstrated a 4-fold reduction of promoter activity in Caco-2 cells and nearly a 6-fold reduction in HuH-7 cells compared with the effect of IP6. In Caco-2 cells, IP7 still exhibited a comparably high relative luciferase activity. The construct IP2, in which the promoter fragment of IP2 was inserted in the opposite direction in pGL3-basic, exhibited less relative luciferase activity than did the promoterless construct pGL3-basic (data not shown).
The addition of insulin (10 nmol/L), T3 (50 nmol/L), dexamethasone (100 nmol/L), or glucagon (5 nmol/L) to the cell culture medium of transfected HuH-7 cells did not significantly alter the reporter gene expression of any of the generated promoter constructs (LP1 to LP7 or IP1 to IP7) (data not shown, 3 independent experiments in triplicate assay each).
The regions Ϫ1144 to Ϫ216 and Ϫ556 to Ϫ216 were deleted from the 5Ј flanking region of exon 2 (IP) by fusing the promoter fragments Ϫ2070 to Ϫ1145 and Ϫ2070 to Ϫ557 directly in front of the promoter construct IP5, thus generating the constructs IP⌬1144 -216 and IP⌬556 -216. In addition, the regions Ϫ1167 to Ϫ266, Ϫ581 to Ϫ266, and Ϫ318 to Ϫ266 of the 5Ј flanking sequences of exon 2 were ligated in front of the promoter construct LP5 to generate the constructs IP(1167-266)-LP5, IP(581-266)-LP5, and IP(318 -266)-LP5.
In a second set of experiments, these 5 additional constructs and the basic constructs IP1, IP5, and LP5 were transfected in HuH-7, Caco-2, and NIH/3T3 cells to determine their promoter activities. The meanϮSEM of 4 independent experiments are each shown in Figure 6C and 6D. In comparison with IP1, IP⌬1144 -216 showed an increased promoter activity similar to that of IP5 in both HuH-7 and Caco-2 cells. This increase was most pronounced in HuH-7 cells, in which IP⌬1144 -216 had an Ϸ3-fold stronger promoter activity than IP1 ( Figure 6C ). IP⌬556 -216 lost promoter strength in both HuH-7 and Caco-2 cells compared with IP⌬1144 -216 and exerted promoter activities similar to those of IP1. In NIH/3T3 cells, all 4 constructs (IP1, IP5, IP⌬1144 -216, and IP⌬556 -216) had low promoter activities, yet in relative terms IP5 and IP⌬1144 to 216 were Ϸ2-fold stronger than IP1 or IP⌬556 -216. Increased amounts of Caco-2 cells (1 to 2ϫ10 6 ) seeded in a 6-well plate and resulting in a very densely packed confluent monolayer of microscopically differentiated Caco-2 cells at day 2 after transfection did not result in higher reporter gene expression of the promoter constructs IP1, IP2, or IP3 (data not shown). 
Transfection of an APOBEC-1 Minigene Containing the 5 Flanking Region of Exon 1 in Human Hepatoma HuH-7 Cells
p-APOBEC-1, which contained the promoter fragment LP1 (Ϫ2535 to ϩ28), the cDNA of rat APOBEC-1 from position Ϫ31 from ATG to position Ϫ699, the SV40 small T-antigen splice site and the SV40 early poly(A) site in the plasmid backbone of pT7T3, and the positive control plasmid pSVL-APOBEC-1, in which APOBEC-1 expression was driven by the SV40 late promoter, were transfected into the human hepatoma cell line HuH-7. Apo B mRNA from transfected and mock-transfected HuH-7 cells was amplified by RT-PCR and assayed by primer extension (Figure 7 ). Apo B mRNA from HuH-7 cells transfected with p-APOBEC-1 was edited in contrast to that of mock-transfected HuH-7 cells, yet the amount of apo B mRNA editing was considerably lower in comparison with HuH-7 cells transfected with pSVL- 
Discussion
The present investigation demonstrates that the tissue-specific expression of APOBEC-1 is a consequence of differential promoter usage in the rat APOBEC-1 gene. The low expression of APOBEC-1 in rat organs other than the intestine, such as the liver, spleen, lung, kidney, or heart is due to a distinct promoter at the 5Ј end of the rat APOBEC-1 gene, which leads to tissue-specific exon use and alternate splicing in the 5Ј UTR of rat hepatic APOBEC-1 mRNA. The second downstream-located promoter specifically promotes strong expression of APOBEC-1 in the intestine but does not contribute significantly to the extraintestinal expression of rat APOBEC-1.
In the rat, APOBEC-1 is expressed not only in the intestine but also in the spleen, liver, kidney, lung, and heart, in contrast to the situation in humans or rabbits. 11, 14, 29 Although most of these organs do not have influence on lipoprotein metabolism, the expression of APOBEC-1 in rat liver with hepatic apo B mRNA editing and the secretion of apo B-48 -containing VLDL has an important impact on speciesspecific LDL levels. 4, 7 Given the importance of LDL for the development of atherosclerosis and coronary artery disease, this topic is of great physiological significance. The current investigation focused on the molecular basis of tissue-specific expression of APOBEC-1 the in rat liver and intestine, the 2 main sources for apo B-containing lipoproteins. The results demonstrate that hepatic expression of APOBEC-1 is due to a distinct promoter in the rat APOBEC-1 gene, which was designated LP. The intestine-specific promoter, termed IP, lacks a typical TATA box in the vicinity of the transcriptional start site but contains a hexanucleotide MED-1 motif (GCTCCC) within the 5Ј UTR downstream from the transcriptional start site. 35 This MED-1 sequence is characteristic for a new class of RNA polymerase II promoter without a canonical TATA box. 35 Overall, our results are in good agreement with 2 other very recent publications on the genomic organization and expression pattern of the rat APOBEC-1 gene. 36, 37 As in the mouse, 17 the rat APOBEC-1 gene appears to have acquired an additional exon with a distinct promoter region that directs expression of APO-BEC-1 in organs other than the intestine. This upstreamlocated promoter LP leads to tissue-specific exon use and alternate splicing within the 5Ј UTR of exon 2, without alteration of the open reading frame of APOBEC-1. According to the data presented, this promoter LP is a "classic" promoter with a canonical TATA box and far less tissue specificity than the downstream promoter IP, which appears to be very specific for the intestine. Qian et al 37 recently reported 2 allelic variants of the rat APOBEC-1 gene, of which the variant RE5 allele lacks the upstream liver-specific promoter. In RE5 transgenic mice, expression of rat APOBEC-1 was dramatically reduced in the liver, kidney, and brain in comparison with mice transgenic for the RE4 allele containing the upstream liver-specific promoter. 37 The presumptive absence of this less-tissue-specific promoter in the human APOBEC-1 gene most probably represents the molecular basis for the restriction of APOBEC-1 expression to the human intestine. 29, 38 The transcriptional start sites for APOBEC-1 in the rat liver and intestine were determined by 5Ј RACE and primer extension analysis. In the liver, primer extension analysis and 5Ј RACE pinpointed the transcriptional start site exclusively within exon 1. Primer extension analysis mapped the transcriptional start site 22 nucleotides upstream from the longest 5Ј RACE product. In the intestine, 5Ј RACE resulted in 3 distinct products, all of which mapped to exon 2. The three 5Ј RACE products differed each in Ϸ20 nucleotides at the 5Ј end. Primer extension analysis of rat intestinal RNA yielded a major and a minor extension product within this region of exon 2. Ribonuclease protection assays confirmed the transcriptional start sites and the splice variants of APOBEC-1 in the rat liver and intestine and proved that the expression of APOBEC-1 in organs such as the spleen, liver, lung, kidney, and heart was driven exclusively by the upstream-located promoter LP. With the use of ribonuclease protection assays, the transcriptional start sites for intestinal APOBEC-1 mRNA were found to be located within exon 2, without any evidence for transcription initiation in exon 1. Three transcriptional start sites were found downstream from the distal splice acceptor site exactly as identified by 5Ј RACE. The fragments of 154, 144, and 103 nucleotides, which are protected in intestinal RNA by the exon 2-specific antisense RNA probe, indicate that the splice acceptor sites of exon 2 are additional sites of transcription initiation in the intestine. This evidence of multiple start site selection for the transcription of APOBEC-1 in the rat intestine further supports the classification of IP as a TATA-less promoter for which multiple transcription initiation is characteristic. 35 The transfection studies in human hepatoma HuH-7 cells and human colonic carcinoma Caco-2 cells further demonstrate that the 2 promoters of the rat APOBEC-1 gene have distinct activities. The liver-specific promoter LP in the 5Ј flanking region of exon 1 had much stronger activities in HuH-7 and NIH/3T3 cells than in Caco-2 cells. Its minimal promoter elements reside within a region Ϸ140 bp from the transcriptional start site, which contains the putative TATA box and the putative CAT box. The organization of LP in the rat is very similar to the upstream-located promoter of the mouse APO-BEC-1 gene, which also contains a variant TATA box 20 nucleotides upstream from the transcriptional start site and an upstream CAT box. 29 In contrast to LP, IP exhibited a 4-fold increased promoter activity in Caco-2 cells in comparison with HuH-7 or NIH/3T3 cells. The constructs IP5 and IP6 had strongly increased promoter activity in both Caco-2 and HuH-7 cells. Negative regulatory elements within the region Ϫ1100 to Ϫ500 of IP were further demonstrated by using the deletion mutants IP⌬1144 -216 and IP⌬556 -216 as well as the crossover mutants IP(1167-266)-LP5, IP(581-266)-LP5, and IP(318 -266)-LP5. This region appears to be a universal negative regulatory element restricting the expression of IP to the intestine. The expression of IP in human colonic carcinoma Caco-2 cells probably underestimates its promoter activity in the small intestine, for which no better-suited cell line was available for this study. The addition of insulin, T3, dexamethasone, or glucagon did not influence reporter gene expression of any of the generated constructs. Whether these results reflect the absence of hormonal regulation of the rat APOBEC-1 gene or are merely due to the tested promoter constructs lacking the appropriate hormonal response elements remains to be investigated. In accordance with the results presented, T3 has been shown to stimulate the editing of rat hepatic apo B mRNA without increasing the expression of APOBEC-1. 23 The modus of hormonal regulation of hepatic apo B mRNA editing in the rat liver appears to be complex, involving both APOBEC-1 and other trans-acting factors. 23 Our results are in some contrast to the recent published study of Hirano et al, 36 who did not observe a major difference in promoter activity of the intestine-specific promoter IP (REX1) between Caco-2 cells and rat hepatoma McArdle7777 cells nor increased promotor activities of their shorter constructs. Although the MED-1 motif was conserved in all promoter constructs of the current study (IP1 to IP7), the constructs of Hirano et al 36 ended exactly within this motif. Whether this or other differences explain this discrepancy remains to be studied.
The liver-specific promoter LP of the rat APOBEC-1 gene is sufficient to induce APOBEC-1 expression in human hepatoma HuH-7 and HepG2 cells. This experiment demonstrates that the lack of a liver-specific promoter within the human APOBEC-1 gene 29, 38 most probably explains the absence of APOBEC-1 expression in the human liver rather than the hypothetical assumption of specific repressors for APOBEC-1 expression. Further characterization of the liver-specific promoter of the rat APOBEC-1 gene in transgenic animals will help to elucidate how APOBEC-1 can be expressed in the liver without harmful effects. The mystery of APOBEC-1 as an oncogene must reside within the regulatory elements of the APOBEC-1 gene from species such as the rat, mouse, dog, or horse, which naturally express APOBEC-1 in the liver. Solving this mystery might revive the prospects for gene therapy with APOBEC-1, which appeared to be gloomy due to the oncogenic threats of APOBEC-1. 
